PROLX Pharmaceuticals Acquires Worldwide Development And Commercialization Rights For Novel Phosphatidylinositol-3-Kinase Inhibitors
10/19/2005 5:10:51 PM
ProlX Pharmaceutical Corp. has received the exclusive worldwide license for the development and marketing rights to the phosphatidylinositol-3-kinase (PI-3K) inhibitor wortmannin and semi-synthetic viridin analogues covered in a number of patents jointly owned by the University of Arizona, the University of Pittsburgh and the Burnham Institute. Under the terms of this agreement, ProlX Pharmaceuticals will share revenues with these institutions from the successful commercialization of the agents covered under the licensed patents.
comments powered by